Skip to main content
. 2023 May 29;26(7):107006. doi: 10.1016/j.isci.2023.107006

Figure 3.

Figure 3

The combination of targeted therapies with tepotinib or TNO155 decreases MAPK/PI3K downstream signaling more potently than either of the agents alone

(A) HCC827 tetON-MET and NCI-H358 tetON-MET, as well as (B) NCI-H1781 tetON-MET and KM12 tetON-MET cells were induced with doxycycline for 48 h before they were treated with the respective inhibitors and combinations for 6 h. Western blot analysis was performed with the indicated antibodies.